Acute lymphoblastic leukemia (ALL) is a challenging cancer, especially when it relapses or becomes resistant to treatment (R/R). This article examines the FDA-approved drug inotuzumab ozogamicin, a significant advancement in treating pediatric R/R B-cell ALL, and explores the evolving therapeutic landscape for this disease. Understanding Acute Lymphoblastic Leukemia (ALL) ALL is a heterogeneous disease marked […]
Tag Archives: car t-cell therapy
Almost a decade ago, the FDA approved daratumumab (Darzalex), a groundbreaking monoclonal antibody for multiple myeloma (MM). This marked a significant shift in the MM treatment landscape, ushering in an era of immunotherapies. Experts at the 2024 International Myeloma Society (IMS) Annual Meeting highlighted the evolution of these treatments, including bispecific and monoclonal antibodies, and […]